Evogene Subsidiary Biomica CEO Steps Down Due to Medical Reasons
Ticker: EVGN · Form: 6-K · Filed: Jun 5, 2025 · CIK: 1574565
Sentiment: neutral
Topics: management-change, subsidiary, medical-leave
TL;DR
Biomica CEO Haber out for medical reasons, Evogene CEO Haviv steps in as interim.
AI Summary
Evogene Ltd. announced changes in its subsidiary Biomica Ltd.'s management on June 5, 2025. Dr. Elran Haber is stepping down as CEO of Biomica due to an unexpected medical condition. Mr. Ofer Haviv, who is also the CEO of Evogene, will assume the role of interim CEO of Biomica.
Why It Matters
This management change at Biomica, a subsidiary focused on microbiome-based drugs, could impact its operational continuity and strategic direction.
Risk Assessment
Risk Level: medium — Management changes, especially unexpected ones due to medical reasons, can introduce uncertainty regarding the subsidiary's operations and future development.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Biomica Ltd. (company) — Subsidiary
- Dr. Elran Haber (person) — Biomica CEO stepping down
- Mr. Ofer Haviv (person) — Evogene CEO and interim Biomica CEO
- June 2025 (date) — Reporting period for management changes
FAQ
What is the reason for Dr. Elran Haber's departure as CEO of Biomica?
Dr. Elran Haber is stepping down as CEO of Biomica due to an unexpected medical condition.
Who will be the interim CEO of Biomica?
Mr. Ofer Haviv, the CEO of Evogene, will serve as the interim CEO of Biomica.
What is the primary business of Biomica Ltd.?
Biomica Ltd. is developing drugs based on the human microbiome.
When was this report filed with the SEC?
This Form 6-K report was filed on June 5, 2025.
Under which form does Evogene Ltd. typically file annual reports?
Evogene Ltd. files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 5, 2025 by Dr. Elran Haber regarding Evogene Ltd. (EVGN).